Radius Health Inc (RDUS) : Graticule Asia Macro Advisors scooped up 2,000 additional shares in Radius Health Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 46,920 shares of Radius Health Inc which is valued at $2,662,241.Radius Health Inc makes up approximately 1.09% of Graticule Asia Macro Advisors’s portfolio.
Other Hedge Funds, Including , Capital Guardian Trust Co added RDUS to its portfolio by purchasing 44 company shares during the most recent quarter which is valued at $2,497.Norges Bank boosted its stake in RDUS in the latest quarter, The investment management firm added 324,720 additional shares and now holds a total of 385,465 shares of Radius Health Inc which is valued at $21,871,284. Radius Health Inc makes up approx 0.01% of Norges Bank’s portfolio.Profund Advisors reduced its stake in RDUS by selling 945 shares or 4.7% in the most recent quarter. The Hedge Fund company now holds 19,156 shares of RDUS which is valued at $1,086,911. Radius Health Inc makes up approx 0.05% of Profund Advisors’s portfolio.
Radius Health Inc opened for trading at $55.02 and hit $55.725 on the upside on Thursday, eventually ending the session at $55.68, with a gain of 1.53% or 0.84 points. The heightened volatility saw the trading volume jump to 8,22,537 shares. Company has a market cap of $2,399 M.
On the company’s financial health, Radius Health Inc reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.94.During the same quarter in the previous year, the company posted $-0.61 EPS.
Many Wall Street Analysts have commented on Radius Health Inc. Maxim Group Downgraded Radius Health Inc on Aug 4, 2016 to ” Sell”, Price Target of the shares are set at $24.H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.